Pharmacogenetic research of individual differences in the occurrence of Paroxetine discontinuation syndrome.

帕罗西汀停药综合征发生个体差异的药物遗传学研究。

• 批准号: 20790405
• 负责人: MURATA Yusuke
• 金额: $ 2.66万
• 依托单位: Fukuoka University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2008
• 资助国家: 日本
• 起止时间: 2008 至 2009
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20790405/
• 关键词: 選択的セロトニン再取込阻害薬; パロキセチン; 大うつ病性障害; 離脱症状; 薬理遺伝学

Paroxetine, a selective serotonin reuptake inhibitor (SSRI), has now become the first-line treatment for depression and anxiety disorder. However, discontinuation syndrome following abrupt withdrawal or dose reduction of SSRIs has been recently documented. There are no studies with regard to assess the relation of SSRI discontinuation syndrome and gene polymorphisms. In this study, we investigated the effect of the serotonin-related genetic polymorphisms on the occurrence of paroxetine discontinuation syndrome. In conclusion, the abrupt stoppage of medication is a major risk factor for the occurrence of paroxetine discontinuation syndrome. In addition, the C(-1019)G polymorphism of the 5-HT1A receptor gene may be related to the occurrence of paroxetine discontinuation syndrome.

帕罗西汀是一种选择性5-羟色胺再摄取抑制剂（SSRI），目前已成为治疗抑郁症和焦虑症的一线药物。然而，最近记录了SSRIs突然停药或剂量减少后的停药综合征。目前还没有关于SSRI停药综合征与基因多态性关系的研究。在这项研究中，我们调查了帕罗西汀相关基因多态性对帕罗西汀停药综合征发生的影响。总之，突然停药是帕罗西汀停药综合征发生的主要危险因素。此外，5-HT 1A受体基因C（-1019）G多态性可能与帕罗西汀停药综合征的发生有关。

项目成果

Effects of the Serotonin 1A, 2A, 2C, 3A, and 3B and Serotonin Transporter Gene Polymorphisms on the Occurrence of Paroxetine Discontinuation Syndrome

• DOI: 10.1097/jcp.0b013e3181c8ae80
• 发表时间: 2010-02-01
• 期刊: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
• 影响因子: 2.9
• 作者: Murata, Yusuke;Kobayashi, Daisuke;Mine, Kazunori
• 通讯作者: Mine, Kazunori

ゆっくりとした減量によりパロキセチンの離脱症状発現を予防できるか?

缓慢减少剂量可以预防帕罗西汀戒断症状吗？

• 发表时间: 2008
• 作者: Murata Y;Kobayashi D;Imuta N;Haraguchi K;Ieiri I;Nishimura R;Koyama S;Mine K.;村田雄介
• 通讯作者: 村田雄介